Profile data is unavailable for this security.
About the company
Zeria Pharmaceutical Co Ltd is a Japan-based company mainly engaged in the development of ethical drug business, consumer healthcare business and other business. The Company operates in two business segments. The Ethical Drug segment is engaged in the research, development, manufacture and sale of ethical drugs. The Consumer Healthcare segment is engaged in the manufacture, purchase and sale of over-the-counter (OTC) drugs, health foods, quasi drugs and cosmetics related to self-medication. The others include insurance agency business and real estate business, as well as various maintenance business such as purchasing and sale of promotional materials.
- Revenue in JPY (TTM)87.31bn
- Net income in JPY9.94bn
- Incorporated1955
- Employees1.75k
- LocationZeria Pharmaceutical Co Ltd10-11, Nihombashi Kobuna-choCHUO-KU 103-8351JapanJPN
- Phone+81 336632351
- Fax+81 336632352
- Websitehttps://www.zeria.co.jp/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Fuji Pharma Co Ltd | 48.85bn | 3.18bn | 33.57bn | 1.66k | 10.34 | 0.7211 | 4.70 | 0.6872 | 130.56 | 130.56 | 2,006.72 | 1,872.09 | 0.5498 | 1.35 | 3.37 | 29,460,190.00 | 3.58 | 4.64 | 5.51 | 6.63 | 39.92 | 41.29 | 6.51 | 8.83 | 0.8282 | 24.96 | 0.4145 | 26.14 | 12.84 | 4.93 | 78.92 | 15.72 | 5.89 | 7.94 |
| Daito Pharmaceutical Co Ltd | 50.64bn | 1.91bn | 34.61bn | 1.07k | 18.31 | 0.6631 | 5.68 | 0.6834 | 62.82 | 62.82 | 1,664.70 | 1,734.24 | 0.6505 | 2.14 | 2.88 | -- | 2.27 | 5.12 | 2.95 | 6.67 | 17.06 | 21.75 | 3.49 | 7.35 | 1.37 | -- | 0.1858 | -- | 7.99 | 2.39 | -42.09 | -13.52 | 20.67 | -- |
| Renascience Inc | 132.69m | 113.43m | 35.29bn | 3.00 | 311.10 | 20.51 | 270.54 | 265.93 | 8.92 | 8.92 | 10.44 | 135.32 | 0.067 | -- | 11.95 | 44,231,000.00 | 5.73 | -8.97 | 6.16 | -9.35 | 97.18 | 84.44 | 85.48 | -107.53 | -- | -588.25 | 0.00 | -- | -31.66 | 13.00 | 143.91 | -- | -- | -- |
| Seikagaku Corp | 39.37bn | 1.21bn | 35.51bn | 1.08k | 28.08 | 0.4661 | 11.06 | 0.9018 | 22.25 | 22.25 | 721.50 | 1,340.97 | 0.4753 | 2.07 | 5.15 | 36,626,980.00 | 1.47 | 3.60 | 1.61 | 3.96 | 48.64 | 52.56 | 3.09 | 7.94 | 3.73 | -- | 0.0052 | 55.17 | 8.73 | 6.57 | -44.46 | -- | 18.48 | 2.90 |
| Cuorips Inc | 175.21m | -644.34m | 49.58bn | 56.00 | -- | 8.95 | -- | 282.97 | -80.64 | -80.64 | 21.89 | 682.90 | 0.0294 | 0.299 | 2.19 | 3,128,661.00 | -10.82 | -- | -11.15 | -- | 96.03 | -- | -368.32 | -- | 28.65 | -17.49 | 0.00 | -- | 658.40 | -- | -1.92 | -- | -- | -- |
| ASKA Pharmaceutical Holdings Co Ltd | 64.14bn | 5.10bn | 69.61bn | 1.63k | 13.45 | 1.05 | 9.47 | 1.09 | 179.94 | 179.94 | 2,262.57 | 2,302.59 | 0.6706 | 1.40 | 4.18 | 39,300,860.00 | 5.33 | 5.50 | 7.26 | 7.07 | 48.86 | 47.56 | 7.95 | 7.98 | 1.39 | -- | 0.1361 | 16.60 | 2.06 | 4.07 | -32.39 | 51.04 | 9.49 | 31.48 |
| Nxera Pharma Co Ltd | 30.87bn | -2.32bn | 78.55bn | 374.00 | -- | 1.16 | 44.48 | 2.54 | -25.83 | -25.83 | 343.68 | 746.05 | 0.2072 | 1.48 | 6.96 | 82,534,760.00 | -1.56 | -1.71 | -1.72 | -1.85 | 73.95 | 84.07 | -7.51 | -10.93 | 3.11 | -- | 0.497 | -- | 125.87 | 24.28 | 32.74 | -- | 40.57 | -- |
| JCR Pharmaceuticals Co Ltd | 33.07bn | -4.76bn | 87.41bn | 987.00 | -- | 1.75 | -- | 2.64 | -38.86 | -38.86 | 267.09 | 386.12 | 0.3194 | 0.5309 | 2.43 | 33,507,600.00 | -4.54 | 5.86 | -7.10 | 9.33 | 65.73 | 73.83 | -14.20 | 13.60 | 0.666 | -26.06 | 0.4466 | 45.13 | -22.86 | 5.94 | -186.42 | -- | 15.37 | 20.11 |
| Kyorin Pharmaceutical Co Ltd | 130.09bn | 9.09bn | 89.98bn | 2.00k | 9.49 | 0.6327 | 6.57 | 0.6917 | 158.16 | 158.16 | 2,264.40 | 2,372.28 | 0.7008 | 1.18 | 2.78 | 65,108,610.00 | 4.89 | 3.34 | 6.25 | 4.16 | 45.77 | 45.89 | 6.98 | 5.11 | 2.01 | -- | 0.1727 | 57.34 | 8.83 | 3.41 | 70.73 | 8.12 | 14.36 | -7.06 |
| Katakura Industries Co Ltd | 40.12bn | 3.92bn | 90.50bn | 941.00 | 21.32 | 0.974 | 13.01 | 2.26 | 120.54 | 120.54 | 1,233.12 | 2,638.59 | 0.2885 | 2.32 | 4.76 | 42,634,430.00 | 2.97 | 2.60 | 3.66 | 3.57 | 37.01 | 37.98 | 10.29 | 9.44 | 2.55 | -- | 0.0947 | 23.42 | -1.37 | -2.19 | 15.73 | 15.27 | -7.22 | 33.03 |
| Mochida Pharmaceutical Co Ltd | 105.16bn | 5.69bn | 109.53bn | 1.51k | 18.77 | 0.8165 | 12.70 | 1.04 | 160.36 | 160.36 | 2,966.32 | 3,686.67 | 0.6595 | 1.62 | 3.16 | 69,734,090.00 | 3.57 | 4.50 | 4.24 | 5.44 | 51.15 | 52.49 | 5.41 | 6.87 | 3.47 | 40.43 | 0.0026 | 43.01 | 2.21 | 0.6516 | 25.03 | 4.34 | 1.98 | 0.00 |
| Zeria Pharmaceutical Co Ltd | 87.31bn | 9.94bn | 110.70bn | 1.75k | 9.25 | 1.03 | 6.32 | 1.27 | 225.42 | 225.42 | 1,980.76 | 2,031.33 | 0.5638 | 1.51 | 3.70 | 50,006,380.00 | 6.44 | 4.67 | 9.95 | 7.47 | 73.25 | 72.17 | 11.42 | 9.02 | 0.9752 | -- | 0.3209 | 28.75 | 15.30 | 7.64 | 28.52 | 27.71 | 16.51 | 6.69 |
| Towa Pharmaceutical Co Ltd | 259.59bn | 18.99bn | 164.85bn | 4.79k | 8.30 | 0.9179 | 4.22 | 0.635 | 385.70 | 385.70 | 5,273.63 | 3,486.39 | 0.5759 | 1.57 | 3.69 | 54,217,630.00 | 4.21 | 3.89 | 5.18 | 5.07 | 36.49 | 37.81 | 7.31 | 6.61 | 1.58 | -- | 0.5737 | 21.52 | 13.89 | 18.65 | 17.39 | 5.53 | 46.23 | 9.73 |
Data as of Jul 18 2025. Currency figures normalised to Zeria Pharmaceutical Co Ltd's reporting currency: Japanese Yen JPY
8.37%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| The Vanguard Group, Inc.as of 31 May 2025 | 1.25m | 2.35% |
| Nomura Asset Management Co., Ltd.as of 03 Jul 2025 | 984.20k | 1.85% |
| Nikko Asset Management Co., Ltd.as of 04 Jul 2025 | 460.20k | 0.87% |
| Daiwa Asset Management Co. Ltd.as of 30 May 2025 | 442.50k | 0.83% |
| Dimensional Fund Advisors LPas of 04 Jul 2025 | 295.80k | 0.56% |
| Norges Bank Investment Managementas of 31 Dec 2024 | 286.87k | 0.54% |
| BlackRock Japan Co. Ltd.as of 03 Jul 2025 | 257.90k | 0.49% |
| Mitsubishi UFJ Asset Management Co., Ltd.as of 03 Jul 2025 | 188.30k | 0.35% |
| BlackRock Fund Advisorsas of 03 Jul 2025 | 146.40k | 0.28% |
| Mellon Investments Corp.as of 03 Jul 2025 | 132.30k | 0.25% |
More ▼
Data from 31 Dec 2024 - 31 Mar 2025Source: FactSet Research Systems Inc.
